Stockscreener 앱 받기
3.4101
0.00%
0.0099
전일 마감가:
$3.42
열려 있는:
$3.41
하루 거래량:
270.82K
Relative Volume:
0.50
시가총액:
$154.10M
수익:
-
순이익/손실:
$-32.74M
주가수익비율:
-4.1587
EPS:
-0.82
순현금흐름:
$-24.89M
1주 성능:
-1.44%
1개월 성능:
-35.35%
6개월 성능:
-71.09%
1년 성능:
-66.57%
1일 변동 폭
$3.39
$3.48
1주일 범위
$3.36
$3.56
52주 변동 폭
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
명칭
Third Harmonic Bio Inc
전화
(209) 727-2457
주소
1700 MONTGOMERY STREET, SAN FRANCISCO
THRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
3.4101 | 154.10M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.18 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
617.51 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.12 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.09 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-07 | 개시 | Raymond James | Outperform |
| 2022-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | 개시 | Cowen | Outperform |
| 2022-10-10 | 개시 | Jefferies | Buy |
| 2022-10-10 | 개시 | Morgan Stanley | Overweight |
모두보기
Third Harmonic Bio Inc 주식(THRD)의 최신 뉴스
Layoff Tracker: Lava, Ryvu Cutting 30% of Their Workforces - BioSpace
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com
Third Harmonic and Inventiva slash workforces - The Pharma Letter
Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks
Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn
Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com
Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Third Harmonic Bio stock tumbles after clinical trial results - Investing.com
Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle
Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate - The Bakersfield Californian
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 -February 11, 2025 at 07:00 am EST - Marketscreener.com
(THRD) Investment Analysis - Stock Traders Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
After Falling -7.79% During The Past Week, Should You Still Buy Third Harmonic Bio Inc (NASDAQ: THRD)? - Marketing Sentinel
Analytical Overview: Orasure Technologies Inc (OSUR)’s Ratios Tell a Financial Story - The Dwinnex
Balance Sheet Insights: Chart Industries Inc (GTLS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Ratios Reveal: Breaking Down Third Harmonic Bio Inc (THRD)’s Financial Health - The Dwinnex
THRD: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Third Harmonic Bio Inc (THRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Third Harmonic Bio Inc 주식 (THRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
1.64%
0.75%
자본화:
|
볼륨(24시간):